Androgenetic alopecia is a condition where a person abnormally loses hair in a well-defined manner (usually starting above both temples) to form that characteristic “M” shaped hairline. Also known as male-pattern baldness, the condition also thins the hair at the crown area and then progress into complete baldness in some cases.
But in recent years, studies have shown that this condition can be treated with a drug known as CB-03-01.
And to know more about this in detail, we are going to discuss the efficacy of CB-03-01 formulation for men with androgenetic alopecia according to the results of a recent study in today’s guide.
Details Of The Study
According to an interventional clinical trial study, 95 random participants aged 18-50 years old were gathered, and all of them are males with androgenetic alopecia. The subjects were then group into batches:
- One batch was instructed to try out an experimental drug that is officially named as CB-03-01 solution 5% (or Cortexolone 17α-Propionate) and applied the drug 2 times a day for 26 weeks.
- Another batch was instructed to use and FDA approved Minoxidil Solution 5% and applied the drug 2 times a day for 26 weeks.
- The last group was instructed to use a Placebo drug (vehicle solution) and applied the drug 2 times a day for 26 weeks.
All participants were also instructed to maintain the same hair style, length, and color and not to try any other hair care products or medication at the duration of the study.
Criteria Limitations
Here are the limitations set to the subjects to ensure accurate results in determining the efficacy of CB-03-01 formuation for men with androgenetic alopecia:
- The participants should not be suffering from any dermatological diseases at the scalp region such as bacterial infections, fungal infections, psoriasis, seborrheic dermatitis, eczema, scars, scalp atrophy, and folliculitis.
- The participants did not undergo any hair weaves, hair transplants, hair bonding, and non-breathable wigs during the last 3 months.
- The participants did not have any other form of alopecia other than AGA
- The participants did not suffer from allergic reactions due to tattoo ink, active, and inactive components.
- They did not undergo any topical preparations before taking the test.
- They are not engaged in excessive alcohol consumption and drug abuse.
What Did The Results Indicate?
The results of the study are compared to the baseline details of each participant and the evaluation of the researchers. To be specific, each subject is given HGSS (Hair Growth Satisfaction Scale) questionnaires and they are compared side by side to the evaluation of the researchers through their HGI (Hair Growth Index) data.
The results show the following:
- The participants who used the placebo drug (vehicle solution) did not exhibit any significant changes in hair growth, thickness, and appearance (up to 16% changes only).
- Those subjects who took Minoxidil showed favorable scalp hair growth in the targeted area after 4 months. Aside from that, minimal skin reactions were also experienced but no sexual side effects were reported.
- Participants who used the CB-03-01 formulation (Cortexolone 17α-Propionate) show the most promising results, up to 39% notable hair growth compared to Minoxidil with a low incidence of local skin reactions.
So it goes to show that CB-03-01 is indeed effective in treating androgenetic alopecia in males, but more studies are still needed to further back up this result.
